Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Traws Pharma, Inc.

Get SEC filing alerts via email and in your feed for Traws Pharma, Inc.

TRAW

Traws Pharma, Inc.

About Traws Pharma, Inc.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing antiviral therapies targeting respiratory viral diseases like influenza and COVID-19. Its key products include investigational agents such as tivoxavir marboxil and ratutrelvir. The company focuses on innovative, safe, and simple-dose treatments, leveraging accelerated clinical strategies to address unmet medical needs in infectious diseases and cancer, with a global licensing and partnership approach.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Traws Pharma, Inc.

1
1
Traws Pharma, Inc. Traws Pharma Reports $7.1 Million Net Loss and No Revenue in Latest Quarter

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Traws Pharma, Inc. Traws Pharma Reports $2.79M Revenue Growth and Strategic Shift to Antiviral Therapies

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Traws Pharma, Inc. Traws Pharma Reports No Revenue for Q3 2025, Net Loss Improves to $3.96 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Traws Pharma, Inc. Traws Pharma Reports $2.73M Revenue for Q2 2025, Net Loss Improves to $915K

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Traws Pharma, Inc. Traws Pharma Reports Net Income Turnaround to $21.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Traws Pharma, Inc. Onconova Therapeutics Reports $166.5 Million Net Loss and Financial Challenges in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Traws Pharma, Inc. Traws Pharma Reports Significant Net Losses and Cash Decline in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments